Hydroxyethyl Starch
- Generic Name
- Hydroxyethyl Starch
- Brand Names
- Hespan, Hextend, Volulyte, Voluven
- Drug Type
- Small Molecule
- CAS Number
- 9005-27-0
- Unique Ingredient Identifier
- 875Y4127EA
- Background
Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume.
HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.
- Indication
An intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood loss caused by trauma, surgery, or other issues.
- Associated Conditions
- Hypovolaemia
- Associated Therapies
- Granulocyte yield increase
Fluid Optimization With Crystalloids and Colloids in Neurosurgery
- Conditions
- Postoperative Complications
- Interventions
- Drug: Sterofundin (Bolus of crystalloids)
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 80
- Registration Number
- NCT03249298
- Locations
- 🇸🇮
University Medical Centre Ljubljana, Ljubljana, Slovenia
The Effects of Intravenous Fluids on Perfusion Index and Pleth Variability Index
- Conditions
- Perfusion
- Interventions
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Tokat Gaziosmanpasa University
- Target Recruit Count
- 93
- Registration Number
- NCT03048162
- Locations
- 🇹🇷
Gaziosmanpasa University, Tokat, Turkey
Endothelial Function After Cardiac Surgery
- Conditions
- Endothelial Dysfunction
- Interventions
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 85
- Registration Number
- NCT02882074
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Colon Surgery
- Conditions
- Colon Surgery
- Interventions
- Drug: Intravenous Crystalloid
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Konkuk University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02770027
Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Cardiac Surgery
- Conditions
- Cardiac Surgery
- Interventions
- Drug: Intravenous Crystalloid
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Konkuk University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02757118
Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for CABG Surgery
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Konkuk University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02757027
Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity
- Conditions
- Cerebral Aneurysm
- Interventions
- Drug: Intravenous Crystalloid
- First Posted Date
- 2016-03-07
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Konkuk University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT02700607
Volume Therapy With Crystalloids and Colloids and Hemodynamic Monitoring in Patients With Severe Sepsis
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Wuerzburg University Hospital
- Registration Number
- NCT02587078
HES and Acute Kidney Injury in Adult Cardiac Surgery
- Conditions
- Acute Kidney Injury After Adult Cardiac Surgery
- Interventions
- Drug: Crystalloid
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- University of Liege
- Target Recruit Count
- 697
- Registration Number
- NCT02445820
Evaluate the Nephrotoxicity by 6% Hydroxyethyl Starch 130/0.4 in Old Patients During Orthopaedic Surgery
- Conditions
- Total Fluid Volume Increased
- Interventions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Yuanyuan Zhang
- Target Recruit Count
- 120
- Registration Number
- NCT02361736
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.